Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

Gene expression profiling of 207 uniformly treated children with high-risk B-progenitor acute lymphoblastic leukemia revealed 29 of 207 cases (14%) with markedly elevated expression of CRLF2 (cytokine receptor-like factor 2). Each of the 29 cases harbored a genomic rearrangement of CRLF2: 18 of 29 (62%) had a translocation of the immunoglobulin heavy chain gene IGH@ on 14q32 to CRLF2 in the pseudoautosomal region 1 of Xp22.3/Yp11.3, whereas 10 (34%) cases had a 320-kb interstitial deletion centromeric of CRLF2, resulting in a P2RY8-CRLF2 fusion. One case had both IGH@-CRLF2 and P2RY8-CRLF2, and another had a novel CRLF2 rearrangement. Only 2 of 29 cases were Down syndrome. CRLF2 rearrangements were significantly associated with activating mutations of JAK1 or JAK2, deletion or mutation of IKZF1, and Hispanic/Latino ethnicity (Fisher exact test, P < .001 for each). Within this cohort, patients with CRLF2 rearrangements had extremely poor treatment outcomes compared with those without CRLF2 rearrangements (35.3% vs 71.3% relapse-free survival at 4 years; P < .001). Together, these observations suggest that activation of CRLF2 expression, mutation of JAK kinases, and alterations of IKZF1 cooperate to promote B-cell leukemogenesis and identify these pathways as important therapeutic targets in this disease.

[1]  J. Downing,et al.  Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.

[2]  Takashi Akasaka,et al.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.

[3]  M. Loh,et al.  JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[4]  P. Pandolfi,et al.  Molecular genetics of acute lymphoblastic leukemia. , 2009, Annual review of pathology.

[5]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[6]  P. Moreau,et al.  Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study. , 2008 .

[7]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[8]  G. Wainreb,et al.  Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome , 2008, The Lancet.

[9]  S. Hunger,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.

[10]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[11]  Leslie L Robison,et al.  Acute lymphoblastic leukaemia , 2018, Radiopaedia.org.

[12]  A. Pardanani.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.

[13]  D. Teachey,et al.  Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. , 2007, Cancer research.

[14]  M. Rocchi,et al.  Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphoma , 2007, Leukemia.

[15]  S. Ziegler,et al.  Local increase in thymic stromal lymphopoietin induces systemic alterations in B cell development , 2007, Nature Immunology.

[16]  R. Tibshirani,et al.  Outlier sums for differential gene expression analysis. , 2007, Biostatistics.

[17]  P. Campbell,et al.  The myeloproliferative disorders. , 2006, The New England journal of medicine.

[18]  Debashis Ghosh,et al.  COPA - cancer outlier profile analysis , 2006, Bioinform..

[19]  C. Pui,et al.  Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.

[20]  J. Downing,et al.  Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[22]  S. Armstrong,et al.  Molecular genetics of acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Cumano,et al.  Pre-B cell receptor expression is necessary for thymic stromal lymphopoietin responsiveness in the bone marrow but not in the liver environment. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[25]  H. Drexler,et al.  Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation , 2001, Leukemia.

[26]  M. Hirai,et al.  Molecular cloning of a human novel type I cytokine receptor related to δ1/TSLPR , 2001, Cytogenetic and Genome Research.

[27]  F. Behm,et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.

[28]  D. Largaespada,et al.  Cloning of the Murine Thymic Stromal Lymphopoietin (Tslp) Receptor , 2000, The Journal of experimental medicine.

[29]  Heinz Baumann,et al.  Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin , 2000, Nature Immunology.

[30]  N. Copeland,et al.  Molecular cloning of a novel type 1 cytokine receptor similar to the common gamma chain. , 2000, Blood.

[31]  A. Look,et al.  Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse , 1999 .

[32]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[33]  R. Perlmutter,et al.  Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism. , 1999, Journal of immunology.

[34]  N. Heerema,et al.  Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies , 1998, Cancer.

[35]  H. Sather,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.

[36]  C. Paige,et al.  Characterization of thymic stromal‐derived lymphopoietin (TSLP) in murine B cell development in vitro , 1996, European journal of immunology.

[37]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Shurtleff,et al.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. , 1995, Leukemia.

[39]  J. Downing,et al.  11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Williams,et al.  A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. , 1994, Experimental hematology.

[41]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .